AYVAKIT® avapritinib 25mg tablets

Join us for a promotional education speaker program about AYVAKIT

AYVAKIT® (avapritinib) is an FDA-approved treatment for adults with Indolent Systemic Mastocytosis (ISM).[1]

During this program, you will hear from an expert who will discuss the following topics:

- Disease State Background and Burden of Disease
- AYVAKIT for the Treatment of Indolent Systemic Mastocytosis
- Fictional Patient Portrayals (Based on AYVAKIT Clinical Trial Experiences)

The FIRST and ONLY Therapy Approved for Adults With Indolent Systemic Mastocytosis (ISM)

Presented (on behalf of Blueprint Medicines) by:

James McCloskey, MD
Chief, Division of Leukemia
John Theurer Cancer Center

Saturday, February 03, 2024, 05:30 PM PST
Hyatt Regency La Jolla at Aventine, 3777 La Jolla Village Drive, San Diego, CA, 92122

Register Here:

You may register for this program by calling or texting Heidi Booth at (805) 701-9703 or emailing hbooth@blueprintmedicines.com.

INDICATION

AYVAKIT® (avapritinib) is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM).

Limitations of Use: AYVAKIT is not recommended for patients with platelet counts of <50 x 10^9/L.

IMPORTANT SAFETY INFORMATION

There are no contraindications for AYVAKIT.

Intracranial Hemorrhage (ICH)—Serious ICH may occur with AYVAKIT treatment; fatal events occurred in <1% of patients. No events of ICH occurred in the 246 patients with ISM who received any dose of AYVAKIT in the PIONEER study.

Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia.

Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH.

Permanently discontinue AYVAKIT if ICH of any grade occurs.

Cognitive Effects—Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC; <1% were Grade 3. Depending on the severity, withhold AYVAKIT and then resume at the same dose, or permanently discontinue AYVAKIT.

Please see additional Important Safety Information on next page, and click here or see accompanying full Prescribing Information for AYVAKIT.

IMPORTANT SAFETY INFORMATION (continued)

Photosensitivity—AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment.

Embryo-Fetal Toxicity—AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective method of contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks after the final dose.

Adverse Reactions—The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing.

Drug Interactions—Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors or inducers.

To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or **www.fda.gov/medwatch**.

If you have questions about this program, call or text Heidi Booth at (805) 701-9703 or email hbooth@blueprintmedicines.com

This promotional education speaker program is only appropriate for individuals who are involved in direct patient management in the practice.

This program is sponsored by Blueprint Medicines and is not accredited for continuing medical education. Blueprint Medicines is committed to complying with all applicable laws and regulations and adhering to the highest standards in its interactions with healthcare professionals. In accordance with the PhRMA Code, Blueprint Medicines will not pay for or provide alcohol in connection with speaker programs; and we are unable to accommodate spouses or guests at this event. This invitation is nontransferable and is for relevant U.S. healthcare professionals only. Blueprint Medicines may restrict your participation in this program.

In order to ensure accurate transparency reporting of meals, Blueprint Medicines may require program attendees to sign in upon arrival. Subject to all applicable federal and/or state regulations, Blueprint Medicines will disclose information related to meals provided to you. In most cases, this information will be made public. Attendees may opt out of the meal by indicating on their RSVP. Minnesota, Vermont, the Department of Defense and the Department of Veteran Affairs have regulations or policies that prohibit the receipt of meals at company sponsored events. You are accountable for understanding such restrictions and complying with them.

For more information on AYVAKIT, visit AYVAKIThcp.com

Please see additional Important Safety Information on previous page, and click here or see accompanying full Prescribing Information for AYVAKIT.

Reference: 1. AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; May 2023.

05/2023 USBP-PRAVAISM-23.054.1